Tryton launches stent system in eight European countries
20 Sept 2010
Tryton Medical, Inc., a developer of stents designed to treat
bifurcation lesions, has launched the Tryton Stent System in
Switzerland, Sweden, Finland, Turkey, Hungary, Czech Republic, Slovakia
The Tryton Side Branch Stent System is designed to offer a
dedicated strategy for treating atherosclerotic lesions in the side
branch at the site of a bifurcation. Tryton’s highly deliverable
cobalt chromium stent is deployed in the side branch artery using a
standard single-wire balloon-expandable stent delivery system. A
conventional drug-eluting stent is then placed in the main vessel.
“We are pleased to expand availability of the Tryton Stent System
to additional countries in Europe and Eastern Europe, broadening our
reach and bringing the Tryton solution to many more patients and
clinicians,” said J. Greg Davis, president and CEO of Tryton
“I have been very pleased with my experience with the Tryton
Stent, which provides a simple solution to a highly complex clinical
problem,” said Imre Ungi, M.D., Ph.D., associate professor and
director of Invasive Cardiology Division, Department of Cardiology
at the University of Szeged in Hungary.
The Tryton Side Branch Stent System demonstrated excellent
six-month clinical and angiographic results in a first-in-man study
of the system and excellent six-month clinical results from almost
200 patients in four different registries with a rate of target
lesion revascularization of less than four percent.
The stent system has received CE Mark approval in Europe and is
commercially available in 21 countries throughout Europe and the
Middle East. It is not approved in the United States.